ATC Group: C09CA Angiotensin II antagonists, plain

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C09CA in the ATC hierarchy

Level
Code
Title
1
Cardiovascular system
2
Agents acting on the renin-angiotensin system
3
Angiotensin II antagonists, plain
4
C09CA
Angiotensin II antagonists, plain

Group C09CA contents

Code
Title
Losartan
Eprosartan
Valsartan
Irbesartan
Tasosartan
Candesartan
Telmisartan
Olmesartan medoxomil
Azilsartan medoxomil

Active ingredients in C09CA

Active Ingredient
Description

Azilsartan medoxomil is an orally active prodrug that is rapidly converted to the active moiety, azilsartan, which selectively antagonises the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues. Angiotensin II is the principal pressor agent of the RAAS, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.

Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.

Eprosartan is a potent, synthetic, orally active non-biphenyl non-tetrazole angiotensin II receptor antagonist, which binds selectively to the AT1 receptor.

Fimasartan, an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound.

Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone concentration.

Losartan is a synthetic oral angiotensin-II receptor (type AT1) antagonist. Antihypertensive activity and suppression of plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade.

Olmesartan medoxomil is a potent, orally active, selective angiotensin II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.

Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist. Telmisartan selectively binds the AT1 receptor. The binding is long-lasting.

Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1-receptor subtype, which is responsible for the known actions of angiotensin II.

Related product monographs

Title
Information Source
Document Type
 
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
European Medicines Agency (EU)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (IE)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)
Health Products Regulatory Authority (IE)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
FDA, National Drug Code (US)
Structured Product Labeling (SPL/PLR)
European Medicines Agency (EU)
Summary of Product Characteristics (SPC)
European Medicines Agency (EU)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (IE)
Summary of Product Characteristics (SPC)
Υπουργείο Υγείας (CY)
Summary of Product Characteristics (SPC)
European Medicines Agency (EU)
Summary of Product Characteristics (SPC)
Pharmaceutical Benefits Scheme (AU)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Health Products Regulatory Authority (IE)
Summary of Product Characteristics (SPC)
Pharmaceutical Benefits Scheme (AU)
Summary of Product Characteristics (SPC)
European Medicines Agency (EU)
Summary of Product Characteristics (SPC)
Medicines & Healthcare Products Regulatory Agency (GB)
Summary of Product Characteristics (SPC)
Web Search
Summary of Product Characteristics (SPC)